Organization Profile

You just read:

OncoGenex Announces Completion of Patient Enrollment in Borealis-2™ Clinical Trial Evaluating Apatorsen in Relapsed or Refractory Metastatic Bladder Cancer

News provided by

OncoGenex Pharmaceuticals, Inc.

Sep 30, 2015, 07:00 ET